Embryyo is a med-tech studio designed to create a pipeline of transformative pure play medical devices, driving them from ideation-to-adoption-to-exit, each with the potential to disrupt standard-of-care in global patient populations. 

WHAT Better / faster / cheaper ways to see / reach / treat the human body will continue to make the established gold standards obsolete and redundant.

WHERE New challenges are hidden at the unique interfaces of contemporary understanding of human physiology, advances in physical sciences that can be reduced to practice and designs that are context-appropriate and empathetic to the end-user.

HOW We are driven to address such challenges with solutions derived from nuanced insights into the problem, based on transformative ideas and realized with entrepreneurial hustle.

WHY The endpoint of all our endeavors is to create multidimensional value which 1) creates quantum shifts in patient care, 2) alleviates cost burdens for the provider and the payer, and 3) generates multifold impact and returns for investors.

In a nutshell, here's what we do - 

Discover

Identify and select novel, unmet medical device opportunities in niche, high-momentum, high-growth clinical sub-domains

Realize

Invent and de-risk early-stage technologies and product concepts and create asset-rich med-tech portfolio companies   

Translate

Commercialize by means of out-licensing and M&A of portfolio companies to strategic partners, maximizing value creation

Learn more ...

We are dauntlessly moving the needle in patient-care, with one medical device at a time!

A quick overview of our asset-classes and ongoing developments and explorations - 

Pre-FDA devices / technologies to be commercialized through out-licensing - 

• Medication dose management for emergency care patients
• Economically viable dialysate delivery system for chronic renal care
• ​Intraoperative quality monitoring systems to improve surgical outcomes
• ​Management of abnormal uterine bleeding in women

Post-FDA devices being self-commercialized through an Embryyo spin-off - 

• ​Lab-in-a-brain platform for the treatment of glioblastoma multiforme​
• Therapeutic oncology management through on-the-go liquid biopsy system
• Biomarker based risk stratification system for critically ill & emergency care patients
• Targeted drug delivery in difficult to reach areas in the lung

Seeding ideas for a healthier planet!(TM)